Kiniksa Pharmaceuticals International Plc (KNSA) concluded trading on Wednesday at a closing price of $27.93, with 0.49 million shares of worth about $13.62 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.27% during that period and on June 18, 2025 the price saw a loss of about -0.07%. Currently the company’s common shares owned by public are about 42.16M shares, out of which, 40.46M shares are available for trading.
Stock saw a price change of -7.58% in past 5 days and over the past one month there was a price change of 4.45%. Year-to-date (YTD), KNSA shares are showing a performance of 41.20% which increased to 48.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $17.38 but also hit the highest price of $30.69 during that period. The average intraday trading volume for Kiniksa Pharmaceuticals International Plc shares is 648.35K. The stock is currently trading -0.88% below its 20-day simple moving average (SMA20), while that difference is up 9.67% for SMA50 and it goes to 21.41% higher than SMA200.
Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) currently have 42.16M outstanding shares and institutions hold larger chunk of about 55.19% of that.
The stock has a current market capitalization of $2.04B and its 3Y-monthly beta is at 0.05. It has posted earnings per share of -$0.24 in the same period. It has Quick Ratio of 3.43 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KNSA, volatility over the week remained 1.51% while standing at 2.78% over the month.
Analysts are in expectations that Kiniksa Pharmaceuticals International Plc (KNSA) stock would likely to be making an EPS of 0.23 in the current quarter, while forecast for next quarter EPS is 0.22 and it is 1.46 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.14 which is 0.37 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.06 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 220.74% while it is estimated to increase by 75.51% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on March 13, 2025 offering a Buy rating for the stock and assigned a target price of $40 to it. Coverage by Jefferies stated Kiniksa Pharmaceuticals International Plc (KNSA) stock as a Buy in their note to investors on September 13, 2024, suggesting a price target of $40 for the stock. On May 03, 2024, Wells Fargo Initiated their recommendations, while on June 29, 2020, BofA Securities Reiterated their ratings for the stock with a price target of $40. Stock get a Buy rating from BofA/Merrill on April 01, 2020.
